XPhyto Therapeutics Closes Acquisition Of Vektor Pharma TF GmbH

XPhyto Therapeutics完成收购德国麻醉药品制造商Vektor Pharma

2019-09-18 13:05:13 CFN Media Group

本文共1435个字,阅读需4分钟

XPhyto Therapeutics Corp. is pleased to announce that it has closed both the definitive share purchase agreement with Vektor Pharma TF GmbH and the equipment purchase agreement entered into with an affiliated company of Vektor, both of which were previously announced by the Company on August 26, 2019. Vektor is a German narcotics manufacturer, importer, and researcher located approximately 170 kilometers west of Munich. For over a decade, the company and its team have been leaders in the design, testing and manufacture of thin-film drug delivery systems, particularly transdermal patches and sub-lingual (oral) strips for the clinical management of pain. Vektor holds a number of valid narcotics licences pursuant to EU GMP certification and other governing regulations: Import Permit for drug dosage forms; Import Permit for cannabis; Manufacturing Permit for clinical samples; Manufacturing Permit for final drug product release; Analytical Permit for chemical and physical testing; Permit to handle narcotic drugs; and a Permit to handle animal tissue. Vektors various narcotics licences include authorizations related to conventional and cannabis-related prescription medications, including but not limited to: Buprenorphine, cannabis, Dronabinol, Fentanyl, Hydromorphone, Oxycodone, and THC. The Vektor transaction will accelerate XPhytos medicinal cannabis import into Germany and its drug delivery expertise, both of which are a critical part of our near-term revenue generation strategy, said Hugh Rogers, CEO of XPhyto. Further, with vape-based delivery systems now associated with significant potential health risks, XPhyto is extremely pleased to combine assets and expertise with Vektor, a specialist in thin-film drug delivery systems. XPhyto is well positioned to capitalize on the next generation of cannabis investment opportunities, primarily clinical validation of safe and effective medicine and emerging European markets. Pursuant to the Agreement and the Equipment Agreement, the consideration is as follows: 1) 350,000 € cash due upon closing; 2) 200,000 common shares due upon closing; 3) 400,000 € units in the capital of the Company at CAD $1.00 per unit (the Payment Units) due upon closing. Each Payment Unit consists of one common share and one common share purchase warrant. The common shares are subject to a three-year escrow matrix. The warrants are exercisable into one common share of the Company at an exercise price of CAD $1.00 per share for a period of three years from closing; 4) 200,000 € in a convertible debenture with a maturity date that is six months from closing bearing an annual interest rate of 2.5%. The debenture is convertible into Payment Units at the option of the holder, at any time prior to the maturity date. Accrued interest will be paid in cash. Each common share purchase warrant is exercisable into one common share at an exercise price of CAD $1.00 per share for a period of three years from the conversion date; and 5) 150,000 € in a convertible debenture with a maturity date that is twelve months from closing bearing an annual interest rate of 2.5%. The debenture is convertible into Payment Units at the option of the holder, at any time prior to the maturity date. Accrued interest will be paid in cash. Each common share purchase warrant is exercisable into one common share at an exercise price of CAD $1.00 per share for a period of three years from the conversion date. Pricing of the securities set out in the Agreement and Equipment Agreement was established pursuant to a price reservation filed with the Canadian Securities Exchange on August 6, 2019. In connection with the transaction, a consulting fee of 200,000 common shares will be paid to an arms-length consultant on closing. About XPhyto Therapeutics Corp. XPhyto is a science-based cannabis company focused on medical formulation, clinical validation, and emerging European markets. XPhytos 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM). XPhyto is pursuing additional opportunities in Germany including cultivation, processing, manufacturing, import, and distribution. In Canada, two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified extraction, isolation, and formulation facilities, drug research and development expertise, as well as commercial analytical testing capability.
XPhyto Therapeutics Corp .高兴地宣布,它已终止与 Vektor Pharma TF GmbH 签订的最终股份购买协议以及与 Vektor 附属公司签订的设备购买协议。两者均由本公司于二零一九年八月二十六日公布。 维克多是一家德国麻醉药品制造商,进口商和研究员位于慕尼黑以西约170公里。十多年来,公司及其团队一直在薄膜给药系统的设计、测试和制造方面处于领先地位,尤其是用于疼痛临床管理的透皮贴片和亚语(口服)条。维克多根据欧盟 GMP 认证和其他管理法规持有多个有效的麻醉药品许可证:药品剂型进口许可证;大麻进口许可证;临床样品制造许可证;最终药品放行制造许可证;化学和物理检测分析许可证;麻醉药品经营许可证;动物组织处理许可证。维克多的各种麻醉药品许可证包括与常规和大麻相关的处方药相关的授权,包括但不限于:布丙诺啡、大麻、 Droptinol 、芬太尼、氢吗啡酮、 Oxychado 和 THC 。 XPhyto 首席执行官休•罗杰斯( Hugh Rogers )表示, Vektor 交易将加速 XPhytos 药用大麻向德国的进口,以及其提供药品的专业知识,这两方面都是我们近期创收战略的关键部分。此外,由于基于 vape 的递送系统现在与重大的潜在健康风险相关联, XPhyto 非常高兴将资产和专业知识与薄膜药物递送系统的专家 Vektor 结合。 XPhyto 完全有能力利用下一代大麻投资机会。主要是安全有效的药物和新兴欧洲市场的临床验证。 根据该协议及设备协议,代价如下:1)350,000欧元;于结算时应付现金;2)于结算时应付200,000股普通股;3)400,000欧元;本公司股本中单位,于结算时应付每单位1.00加元(付款单位)。每个支付单元由一个普通股和一个普通股购买权证组成。普通股服从三年托管矩阵。认股权证可按行使价每股1.00加元行使为本公司一股普通股,行使价为自收市起三年;4)200,000欧元;可转换债券,到期日为自收市起六个月,年利率为2.5%。债券可在到期日之前的任何时间由持有人选择转换为支付单位。应计利息将以现金支付。每一份普通股购买认股权证可于转换日起三年内以每股1.00加元的行使价行使为一股普通股;及(5)150,000欧元;可换股债券,到期日为自收市起十二个月,年利率为2.5%。债券可在到期日之前的任何时间由持有人选择转换为支付单位。应计利息将以现金支付。每股普通股购买认股权证可于转换日起三年内按行使价每股 CAD $1.00行使为一股普通股。 协议和设备协议中规定的证券定价是根据2019年8月6日向加拿大证券交易所提交的价格保留建立的。 就该交易而言,200,000股普通股的咨询费将于交易结束时支付给一名独立顾问。 关于 XPhyto Therapeutics Corp 。 XPhyto 是一家以科学为基础的大麻公司,专注于医药制剂、临床验证和新兴欧洲市场。XPhytos 100%控股的德国子公司 Bunker Pfranzenkatekte GmbH 已获得德国联邦药物和医疗器械研究所( BfArM )颁发的用于科学目的的独特的德国大麻种植和提取许可证。XPhyto 正在德国寻求更多的机会,包括种植、加工、制造、进口和分销。在加拿大,与加拿大一所主要大学的药剂系进行了两次为期5年的独家合作,提供了经认证的提取、隔离和制剂设施、药物研发专业知识以及商业分析测试能力。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文